We describe a patient with two recent episodes of tenofovir disoproxil fumarate (TDF)-associated acute kidney injury and six-class drug-resistant HIV infection who achieved and maintained viral suppression without worsening kidney function on a regimen including tenofovir alafenamide (TAF) through 48 weeks of therapy. The safety and efficacy of TAF in patients with TDF-associated renal tubulopathy and multiple drug resistant HIV has not yet been described. TAF may represent a useful option to maximally suppress HIV in patients with these complications.
References
1.
HallA.M., HendryB.M., NitschD., ConnollyJ.O.Tenofovir-associated kidney toxicity in HIV-infected patients: a review of the evidence.Am J Kidney Dis2011; 57: 773–780.
2.
MoyleG.J., StellbrinkH.J., CompstonJ.96-Week results of abacavir/lamivudine versus tenofovir/emtricitabine, plus efavirenz, in antiretroviral-naive, HIV-1-infected adults: ASSERT study.Antivir Ther2013; 18: 905–913.
3.
HuangJ.S., HughesM.D., RiddlerS.A., HaubrichR.H.Bone mineral density effects of randomized regimen and nucleoside reverse transcriptase inhibitor selection from ACTG A5142.HIV Clin Trials2013; 14: 224–234.
4.
MarkowitzM., ZolopaA., SquiresK.Phase I/II study of the pharmacokinetics, safety and antiretroviral activity of tenofovir alafenamide, a new prodrug of the HIV reverse transcriptase inhibitor tenofovir, in HIV-infected adults.J Antimicrob Chemother2014; 69: 1362–1369.
5.
SaxP.E., WohlD., YinM.T.Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, Phase 3, non-inferiority trials.Lancet2015; 385: 2606–2615.
6.
MillsA., ArribasJ.R., Andrade-VillanuevaJ.Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, Phase 3, non-inferiority study.Lancet Infect Dis2016; 16: 43–52.
7.
CastagnaA., MaggioloF., PencoG.Dolutegravir in antiretroviral-experienced patients with raltegravir- and/or elvitegravir-resistant HIV-1: 24-week results of the Phase III VIKING-3 study.J Infect Dis2014; 210: 354–362.
WainbergM., AnstettK., MespledeT., QuashieP., HanY., OliveiraM.The R263K mutation in HIV integrase that is selected by dolutegravir may actually prevent clinically relevant resistance to this compound.J Int AIDS Soc2014; 17Suppl 3: 19518.
10.
FouratiS., CharpentierC., AmielC.Cross-resistance to elvitegravir and dolutegravir in 502 patients failing on raltegravir: a French national study of raltegravir-experienced HIV-1-infected patients.J Antimicrob Chemother2015; 70: 1507–1512.
11.
DeeksE.D.Darunavir: a review of its use in the management of HIV-1 infection.Drugs2014; 74: 99–125.
12.
KatlamaC., EspositoR., GatellJ.M.Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1.AIDS2007; 21: 395–402.
13.
EronJ.J., ClotetB., DurantJ.Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study.J Infect Dis2013; 207: 740–748.
14.
MargotN.A., JohnsonA., MillerM.D., CallebautC.Characterization of HIV-1 resistance to tenofovir alafenamide (TAF) in vitro.Antimicrob Agents Chemother2015; 59: 5917–5924.
15.
BamR.A., YantS.R., CihlarT.Tenofovir alafenamide is not a substrate for renal organic anion transporters (OATs) and does not exhibit OAT-dependent cytotoxicity.Antivir Ther2014; 19: 687–692.
16.
MillsA., CrofootG.Jr., McDonaldC.Tenofovir alafenamide versus tenofovir disoproxil fumarate in the first protease inhibitor-based single-tablet regimen for initial HIV-1 therapy: a randomized Phase 2 study.J Acquir Immune Defic Syndr2015; 69: 439–445.
17.
RuaneP.J., DeJesusE., BergerD.Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults.J Acquir Immune Defic Syndr2013; 63: 449–455.
18.
PozniakA., ArribasJ.R., GatheJ.Switching to tenofovir alafenamide, coformulated with elvitegravir, cobicistat, and emtricitabine, in HIV-infected patients with renal impairment: 48 week results from a single-arm, multi-center, open-label, Phase 3 study.J Acquir Immune Defic Syndr2016; 71: 530–537.
19.
KoteffJ., BorlandJ., ChenS.A Phase 1 study to evaluate the effect of dolutegravir on renal function via measurement of iohexol and para-aminohippurate clearance in healthy subjects.Br J Clin Pharmacol2013; 75: 990–996.
20.
BhasinB., LauB., AttaM.G.HIV viremia and T-cell activation differentially affect the performance of glomerular filtration rate equations based on creatinine and cystatin C.PLoS ONE2013; 8: e82028.
21.
LucasG.M., RossM.J., StockP.G.Clinical practice guideline for the management of chronic kidney disease in patients infected with HIV: 2014 update by the HIV Medicine Association of the Infectious Diseases Society of America.Clin Infect Dis2014; 59: e96–e138.
